A highly potent human neutralizing antibody prevents vertical transmission of Rift Valley fever virus in a rat model

Abstract

Rift Valley fever virus (RVFV) is an emerging mosquito-transmitted virus that circulates in livestock and humans in Africa and the Middle East. Outbreaks lead to high rates of miscarriages in domesticated livestock. Women are also at risk of vertical virus transmission and late-term miscarriages. MAb RVFV-268 is a highly potent recombinant neutralizing human monoclonal antibody that targets RVFV. Here we show that mAb RVFV-268 reduces viral replication in rat placenta explant cultures and prevents vertical transmission in a rat model of congenital RVF. Passive transfer of mAb RVFV-268 from mother to fetus occurs as early as 6 h after administration and persists through 24 h. Administering mAb RVFV-268 2 h prior to RVFV challenge or 24 h post-challenge protects the dams and offspring from RVFV infection. These findings support mAb RVFV-268 as a pre- and post-infection treatment to subvert RVFV infection and vertical transmission, thus protecting the mother and offspring.

Introduction

Rift Valley fever (RVF) is an emerging zoonotic disease afflicting humans and livestock (primarily sheep, goats, cattle, camels) throughout Africa and regions of the Arabian Peninsula1,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Al-Azraqi, T. A., El Mekki, A. A. & Mahfouz, A. A. Rift Valley fever among children

Continue reading on Nature

Published
Categorized as Virology

Leave a Reply